PRTA Prothena Corporation plc Stock Quote

PRTA [NASD]

Index	-	P/E	-	EPS (ttm)	-3.11	Insider Own	0.05%	Shs Outstand	40.25M	Perf Week	3.69%
Market Cap	2.08B	Forward P/E	-	EPS next Y	-3.35	Insider Trans	-	Shs Float	20.72M	Perf Month	113.25%
Income	-124.30M	PEG	-	EPS next Q	0.55	Inst Own	91.70%	Short Float	8.29%	Perf Quarter	101.34%
Sales	0.90M	P/S	2316.23	EPS this Y	-43.00%	Inst Trans	14.61%	Short Ratio	3.83	Perf Half Y	272.62%
Book/sh	5.83	P/B	8.48	EPS next Y	-181.10%	ROA	-34.40%	Target Price	49.63	Perf Year	398.59%
Cash/sh	8.13	P/C	6.08	EPS next 5Y	-0.60%	ROE	-57.60%	52W Range	9.39 - 59.74	Perf YTD	311.41%
Dividend	-	P/FCF	-	EPS past 5Y	-0.90%	ROI	-61.10%	52W High	-17.29%	Beta	1.46
Dividend %	-	Quick Ratio	15.00	Sales past 5Y	-11.90%	Gross Margin	-	52W Low	426.20%	ATR	3.94
Employees	66	Current Ratio	15.00	Sales Q/Q	100.00%	Oper. Margin	-	RSI (14)	67.13	Volatility	12.89% 10.46%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-54.50%	Profit Margin	-	Rel Volume	1.04	Prev Close	51.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 AMC	Payout	-	Avg Volume	448.20K	Price	49.41
Recom	1.70	SMA20	34.25%	SMA50	69.53%	SMA200	166.64%	Volume	466,645	Change	-3.14%

Jun-18-21

Upgrade

BofA Securities

Underperform → Neutral

$12 → $49

Jun-08-21

Reiterated

Oppenheimer

Outperform

$45 → $54

May-26-21

Initiated

Citigroup

Buy

$39

Feb-26-21

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$14 → $28

Feb-12-21

Upgrade

Jefferies

Hold → Buy

$15 → $30

Feb-02-21

Upgrade

BTIG Research

Neutral → Buy

$29

Dec-07-20

Initiated

H.C. Wainwright

Buy

$22

Jul-09-20

Upgrade

Oppenheimer

Perform → Outperform

$16

Nov-19-19

Upgrade

Evercore ISI

In-line → Outperform

$14

May-21-18

Downgrade

Barclays

Equal Weight → Underweight

$14 → $12

Apr-23-18

Downgrade

Jefferies

Buy → Hold

Apr-05-18

Reiterated

Barclays

Overweight

$70 → $50

Nov-20-17

Downgrade

Wedbush

Outperform → Neutral

$75 → $55

Sep-29-17

Reiterated

BTIG Research

Buy

$80 → $77

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$87

Aug-17-17

Initiated

Evercore ISI

Outperform

$83

Jul-11-17

Initiated

Jefferies

Buy

Apr-12-17

Initiated

Piper Jaffray

Overweight

$69

Apr-12-17

Initiated

Cantor Fitzgerald

Overweight

$86

Mar-02-17

Initiated

Instinet

Buy

$87

Jun-18-21 04:53AM	Prothena Corp: Why Jeffries Analyst Almost Doubled His Price Target On the Stock? TipRanks
Jun-10-21 04:19PM	Why Biogen, Lilly, and Prothena Stocks Soared This Week Motley Fool +14.33%
02:18PM	Prothena to Participate in JMP Securities Life Sciences Conference on June 16 GlobeNewswire
11:30AM	Prothena (PRTA) Up 78.2% Since Last Earnings Report: Can It Continue? Zacks
Jun-09-21 04:58AM	Prothena (PRTA) Moves 5.9% Higher: Will This Strength Last? Zacks
May-20-21 04:05PM	Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors GlobeNewswire
May-12-21 03:32PM	Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus Zacks
May-11-21 04:05PM	Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update GlobeNewswire
06:57AM	Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing Benzinga
May-10-21 04:05PM	Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinsons Disease GlobeNewswire
10:40AM	Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More Zacks
May-07-21 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:52AM	Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View Zacks
May-04-21 04:05PM	Prothena to Report First Quarter 2021 Financial Results on May 11th GlobeNewswire -8.47%
Apr-28-21 12:33PM	Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline Zacks +6.05%
Apr-18-21 03:05PM	Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 GlobeNewswire
Apr-15-21 04:05PM	Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021 GlobeNewswire +7.05%
Apr-07-21 04:05PM	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.53%
Apr-05-21 04:05PM	Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer GlobeNewswire
Mar-29-21 08:22AM	What Type Of Shareholders Make Up Prothena Corporation plc's (NASDAQ:PRTA) Share Registry? Simply Wall St. -9.67%
Mar-25-21 11:37AM	Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar? Zacks +11.18%
Mar-24-21 08:00AM	Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares GlobeNewswire +16.84%
Mar-23-21 04:29PM	Prothena Announces Proposed Offering of Ordinary Shares GlobeNewswire -11.41%
Mar-13-21 10:30AM	Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report? Zacks
Mar-11-21 08:19AM	The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga +6.53%
Mar-08-21 04:05PM	Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021 GlobeNewswire
Feb-24-21 04:05PM	Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021 GlobeNewswire +8.72%
Feb-12-21 05:11PM	Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks +45.54%
Feb-11-21 09:19AM	Recap: Prothena Corp Q4 Earnings Benzinga
09:15AM	Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:00AM	Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update GlobeNewswire
06:30AM	Prothena Corp. Plc to Host Earnings Call ACCESSWIRE
Feb-05-21 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-04-21 04:05PM	Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th GlobeNewswire
Feb-03-21 12:30PM	Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline Zacks
Feb-01-21 04:15PM	Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA GlobeNewswire
Dec-09-20 08:00AM	Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis GlobeNewswire
Dec-04-20 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
11:31AM	Why Is Prothena (PRTA) Down 19.9% Since Last Earnings Report? Zacks
Nov-27-20 12:25AM	This Just In: Analysts Are Boosting Their Prothena Corporation plc (NASDAQ:PRTA) Outlook for Next Year Simply Wall St.
Nov-16-20 02:56AM	Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation Simply Wall St.
Nov-05-20 11:13AM	Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates Zacks
Nov-04-20 06:35PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates Zacks +22.71%
04:05PM	Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update GlobeNewswire
08:30AM	Prothena Announces Presentations on Two Programs from its Alzheimers Disease Portfolio at CTAD 2020 GlobeNewswire
Oct-28-20 04:05PM	Prothena to Report Third Quarter 2020 Financial Results on November 4 GlobeNewswire
Oct-21-20 10:48AM	Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II Zacks +6.13%
08:04AM	The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga
Oct-20-20 04:05PM	Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinsons Disease GlobeNewswire
Oct-02-20 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-29-20 02:35PM	Hedge Funds Never Been This Bullish On Prothena Corporation plc (PRTA) Insider Monkey
Sep-15-20 08:30AM	Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress GlobeNewswire
Sep-11-20 08:30AM	Prasinezumab Slows Progression on Measures of Parkinsons Disease in Phase 2 Study GlobeNewswire
Sep-08-20 04:05PM	Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15 GlobeNewswire -7.37%
Sep-05-20 11:31AM	Prothena (PRTA) Up 2.9% Since Last Earnings Report: Can It Continue? Zacks
Sep-03-20 04:05PM	Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinsons Disease and Movement Disorders GlobeNewswire
Sep-02-20 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-06-20 08:10PM	Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.09%
04:05PM	Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update GlobeNewswire
Aug-05-20 04:05PM	Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinsons Disease and Movement Disorders GlobeNewswire
Aug-03-20 12:09PM	Were Hedge Funds Right About Selling Prothena Corporation plc (PRTA)? Insider Monkey
Jul-30-20 04:05PM	Prothena to Report Second Quarter 2020 Financial Results on August 6 GlobeNewswire
Jul-28-20 12:33PM	Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-10-20 08:34AM	Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session Zacks -5.96%
Jun-19-20 12:47PM	Hedge Funds Are Dumping Prothena Corporation plc (PRTA) Insider Monkey
May-27-20 04:05PM	Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3 GlobeNewswire
May-18-20 07:26AM	Industry Analysts Just Upgraded Their Prothena Corporation plc (NASDAQ:PRTA) Revenue Forecasts By 92% Simply Wall St.
May-06-20 07:45PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance GlobeNewswire
Apr-29-20 04:05PM	Prothena to Report First Quarter 2020 Financial Results on May 6 GlobeNewswire
Apr-28-20 12:33PM	Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for Zacks -8.53%
Apr-24-20 04:30PM	Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19 GlobeNewswire
Apr-22-20 09:15AM	Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinsons Disease GlobeNewswire
Apr-21-20 10:20AM	Should You Be Pleased About The CEO Pay At Prothena Corporation plc's (NASDAQ:PRTA) Simply Wall St.
Apr-03-20 04:05PM	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -10.08%
Mar-31-20 04:05PM	Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinsons Disease to be Presented at AAT-AD/PD GlobeNewswire
Mar-13-20 11:30AM	Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound? Zacks
Mar-03-20 04:05PM	Prothena Announces Appointment of Brandon Smith as Chief Business Officer GlobeNewswire
Feb-17-20 06:31PM	Edited Transcript of PRTA earnings conference call or presentation 12-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-13-20 10:45AM	Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
Feb-12-20 05:35PM	Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update GlobeNewswire
02:30PM	Prothena Corp. Plc to Host Earnings Call ACCESSWIRE
Feb-05-20 04:05PM	Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12 GlobeNewswire
Jan-20-20 11:21AM	Imagine Owning Prothena (NASDAQ:PRTA) And Trying To Stomach The 71% Share Price Drop Simply Wall St.
Dec-30-19 08:35AM	Options Traders Expect Huge Moves in Prothena (PRTA) Stock Zacks
Dec-11-19 03:47PM	Did Hedge Funds Drop The Ball On Prothena Corporation plc (PRTA) ? Insider Monkey
Dec-05-19 04:05PM	Prothena Announces Appointment of Oleg Nodelman to its Board of Directors GlobeNewswire
11:31AM	Why Is Prothena (PRTA) Up 36.1% Since Last Earnings Report? Zacks
Nov-19-19 11:03AM	Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +5.47%
Nov-06-19 03:14PM	Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3 Zacks
Nov-05-19 06:55PM	Prothena (PRTA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update GlobeNewswire
Oct-29-19 04:05PM	Prothena to Report Third Quarter 2019 Financial Results on November 5 GlobeNewswire
10:32AM	Prothena (PRTA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-15-19 01:49AM	Neil Woodfords empire implodes as he quits last two funds Financial Times +5.32%
Oct-07-19 09:00AM	Labaton Sucharow LLP and Levi & Korsinsky LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Ordinary Shares of Prothena Corporation plc in In re Prothena Corporation plc Securities Litigation, No. 1:18-cv-06425-ALC PR Newswire
Sep-20-19 01:04PM	How Should Investors React To Prothena Corporation plc's (NASDAQ:PRTA) CEO Pay? Simply Wall St.
Sep-11-19 01:39PM	4 Negative Enterprise Value Stocks GuruFocus.com
Sep-05-19 09:31AM	Why Is Prothena (PRTA) Down 8.9% Since Last Earnings Report? Zacks +5.85%

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	Mar 24	Buy	20.75	875,000	18,156,250	11,034,280	Mar 25 11:14 AM
EcoR1 Capital, LLC	10% Owner	Feb 24	Buy	22.02	10,800	237,867	10,159,280	Feb 25 06:00 PM
EcoR1 Capital, LLC	10% Owner	Feb 23	Buy	21.05	44,400	934,518	10,148,480	Feb 25 06:00 PM
Zago Wagner M.	Chief Scientific Officer	Feb 18	Option Exercise	6.41	7,540	48,331	7,540	Feb 19 06:39 PM
EcoR1 Capital, LLC	10% Owner	Feb 18	Buy	3.68	44,100	162,103	10,104,080	Feb 22 04:24 PM
Zago Wagner M.	Chief Scientific Officer	Feb 18	Sale	25.50	7,540	192,270	0	Feb 19 06:39 PM
EcoR1 Capital, LLC	10% Owner	Feb 17	Buy	23.46	198,840	4,665,542	10,059,980	Feb 17 07:14 PM
EcoR1 Capital, LLC	10% Owner	Feb 16	Buy	22.78	89,200	2,031,967	9,861,140	Feb 17 07:14 PM
Zago Wagner M.	Chief Scientific Officer	Feb 12	Option Exercise	11.48	26,310	302,147	18,750	Feb 17 06:47 PM
EcoR1 Capital, LLC	10% Owner	Feb 12	Buy	20.16	345,300	6,959,761	9,771,940	Feb 17 07:14 PM
Zago Wagner M.	Chief Scientific Officer	Feb 12	Sale	19.16	26,310	504,057	0	Feb 17 06:47 PM
Kinney Gene G.	President and CEO	Aug 17	Option Exercise	6.41	10,000	64,100	12,793	Aug 19 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience